Clinical evolution during the tocilizumab period.
| Week 0 | Week 2 | Week 12 | p, Week 0 vs Week 12 | |
|---|---|---|---|---|
| PMR-AS | 36.6 (30.4–43.8) | 19.7 (14.9–27.7) | 4.5 (3.2–6.8) | < 0.001 |
| CRP, mg/dl | 65.1 (21.6–127.8) | 0.5 (0.3–1.4) | 0.2 (0.1–1.0) | < 0.001 |
| Patient VAS for pain | 6.4 (4.6–7.8) | 5.4 (3.8–6.9) | 1.7 (0.6–2.7) | < 0.001 |
| Patient VAS for disease activity | 6.6 (4.8–7.5) | 5.45 (3.8–6.9) | 2.0 (0.9–3.6) | < 0.001 |
| Physician VAS for disease activity | 6.8 (6.0–7.9) | 4.4 (2.8–6.6) | 1.1 (0.8–1.8) | < 0.001 |
| MST, min | 180.0 (75.0–180.0) | 60.0 (60.0–120.0) | 4.0 (0.0–10.0) | < 0.001 |
| EUL | 0.5 (0.0–2.0) | 0.0 (0.0–2.0) | 0.0 (0.0–0.0) | |
| 0, n (%) | 10 (50.0) | 11 (55.0) | 18 (90.0) | |
| 1, n (%) | 2 (10.0) | 3 (15.0) | 2 (10.0) | |
| 2, n (%) | 8 (40.0) | 6 (30.0) | 0 (0.0) | 0.002 |
| 3, n (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Data are median (interquartile range), except where otherwise indicated. PMR-AS: Polymyalgia Rheumatica Disease Activity Score; VAS: visual analog scale; MST: morning stiffness; EUL: scale for elevation of the upper limbs; CRP: C-reactive protein.